サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：先天性心疾患の世界市場予測（2022年～2028年）
市場調査レポート
商品コード
1123172

先天性心疾患の世界市場予測（2022年～2028年）

Global Congenital Heart Disease Market Research and Forecast 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 110 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.46円
先天性心疾患の世界市場予測（2022年～2028年）
出版日: 2022年07月23日
発行: Orion Market Research
ページ情報: 英文 110 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の先天性心疾患の市場規模は、予測期間中に約9.1%の大幅なCAGRで成長すると予測されています。

先天性心疾患（CHD）を持つ赤ちゃんの25％が重症CHDであると言われており、重症CHDの乳児は一般的に生後1年以内に手術やその他の侵襲的な処置が必要となります。先進国の複数の業界企業が欠陥治療のための機器を導入する見通しで、また新興国における医療費の増加も予測期間中に市場に機会をもたらすと考えられています。しかし、この疾患に関する認知度の低さが、市場の成長を妨げています。

当レポートでは、世界の先天性心疾患市場について調査分析し、市場概要、セグメント・地域別の市場分析、競合情勢、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 レポートの概要

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向

第3章 競合情勢

  • 主要企業分析
  • 主要戦略分析
  • COVID-19が主要企業に与える影響

第4章 市場決定要因

  • 促進要因
  • 抑制要因
  • 機会

第5章 市場の内訳

  • 世界の先天性心疾患市場：欠陥タイプ別
    • 心臓弁の欠陥
    • 心臓壁の欠陥
    • 血管の欠陥
  • 世界の先天性心疾患市場：診断別
    • 心エコー図
    • 胸部X線
    • MRIスキャン
    • その他
  • 世界の先天性心疾患市場：治療別
    • 投薬
    • 埋め込み型心臓装置
    • カテーテル処置
    • 開心術
    • 心臓移植
  • 世界の先天性心疾患市場：エンドユーザー別
    • 病院・クリニック
    • 診断センター
    • その他

第6章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • 世界のその他の地域

第7章 企業プロファイル

  • Abbott Laboratories
  • AstraZeneca Plc
  • Becton Dickson & Co.
  • Bio-Rad Laboratories
  • Boston Scientific Corp.
  • Laboratory Corporation of America Holdings（LabCorp）
  • F. Hoffmann-La Roche Ltd.
  • Glaxosmithkline Plc
  • Janssen Pharmaceuticals, Inc.
  • Medtronic
  • Viatris Inc.
  • Novartis Ag
  • Pfizer, Inc.
  • Randox Laboratories Ltd.
  • Response Biomedical Corporation
  • Sanofi S.A.
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.
  • Vericel Corporation
図表

LIST OF TABLES

  • 1. GLOBAL CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS, 2020-2027($ MILLION)
  • 2. GLOBAL CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DEFECT TYPE, 2020-2027($ MILLION)
  • 3. GLOBAL HEART VALVE DEFECTS IN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 4. GLOBAL HEART WALL DEFECTS IN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 5. GLOBAL BLOOD VESSEL DEFECTS IN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 6. GLOBAL CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027($ MILLION)
  • 7. GLOBAL ECHOCARDIOGRAM INCONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 8. GLOBAL CHEST X-RAY IN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 9. GLOBAL MRI SCAN IN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 10. GLOBAL OTHERS IN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 11. GLOBAL CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027($ MILLION)
  • 12. GLOBAL MEDICATIONS FOR CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 13. GLOBAL IMPLANTABLE HEART DEVICES FOR CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 14. GLOBAL CATHETER PROCEDURES FOR CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 15. GLOBAL OPEN-HEART SURGERY FOR CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 16. GLOBAL HEART TRANSPLANT FOR CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 17. GLOBAL CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)
  • 18. GLOBAL HOSPITALS AND CLINICS IN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 19. GLOBAL DIAGNOSTIC CENTRES IN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 20. GLOBAL OTHER IN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 21. NORTH AMERICAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 22. NORTH AMERICAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DEFECT TYPE, 2020-2027($ MILLION)
  • 23. NORTH AMERICAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027($ MILLION)
  • 24. NORTH AMERICAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027($ MILLION)
  • 25. NORTH AMERICAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)
  • 26. EUROPEAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 27. EUROPEAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DEFECT TYPE, 2020-2027($ MILLION)
  • 28. EUROPEAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027($ MILLION)
  • 29. EUROPEAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027($ MILLION)
  • 30. EUROPEAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)
  • 31. ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 32. ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DEFECT TYPE, 2020-2027($ MILLION)
  • 33. ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027($ MILLION)
  • 34. ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027($ MILLION)
  • 35. ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)
  • 36. REST OF THE WORLD CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 37. REST OF THE WORLD CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DEFECT TYPE, 2020-2027($ MILLION)
  • 38. REST OF THE WORLD CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027($ MILLION)
  • 39. REST OF THE WORLD CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027($ MILLION)
  • 40. REST OF THE WORLD CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL CONGENITAL HEART DISEASE MARKET, 2020-2027($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL CONGENITAL HEART DISEASE MARKET BY SEGMENT, 2020-2027($ MILLION)
  • 3. RECOVERY OF GLOBAL CONGENITAL HEART DISEASE MARKET, 2021-2027(%)
  • 4. GLOBAL CONGENITAL HEART DISEASE MARKET SHARE BY DEFECT TYPE, 2020 VS 2027(%)
  • 5. GLOBAL CONGENITAL HEART DISEASE MARKET SHARE BY DIAGNOSIS, 2020 VS 2027(%)
  • 6. GLOBAL CONGENITAL HEART DISEASE MARKET SHARE BY TREATMENT, 2020 VS 2027(%)
  • 7. GLOBAL CONGENITAL HEART DISEASE MARKET SHARE BY GEOGRAPHY, 2020 VS 2027(%)
  • 8. GLOBAL HEART VALVE DEFECTS IN CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 9. GLOBAL HEART WALL DEFECTS IN CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 10. GLOBAL BLOOD VESSEL DEFECTS INCONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 11. GLOBAL ECHOCARDIOGRAM IN FOR CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 12. GLOBAL CHEST X-RAY IN CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 13. GLOBAL MRI SCAN IN CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 14. GLOBAL OTHERS IN CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 15. GLOBAL MEDICATIONS FOR CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 16. GLOBAL IMPLANTABLE HEART DEVICES FOR CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 17. GLOBAL CATHETER PROCEDURES FOR CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 18. GLOBAL OPEN-HEART SURGERY FOR CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 19. GLOBAL HEART TRANSPLANT FOR CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 20. GLOBAL HOSPITALS AND CLINICS IN CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 21. GLOBAL DIAGNOSTIC CENTRES IN CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 22. GLOBAL OTHER IN CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 23. US CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
  • 24. CANADA CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
  • 25. UK CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
  • 26. FRANCE CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
  • 27. GERMANY CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
  • 28. ITALY CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
  • 29. SPAIN CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
  • 30. REST OF EUROPE CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
  • 31. INDIA CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
  • 32. CHINA CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
  • 33. JAPAN CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
  • 34. SOUTH KOREA CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
  • 35. REST OF ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
  • 36. REST OF THE WORLD CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
目次
Product Code: OMR2018284

Global Congenital Heart Diseases Market, By Defect Type (Heart Valve Defects, Heart Wall Defects, Blood Vessel Defects, By Diagnosis (Echocardiogram, Chest X-ray, MRI, and Others), By Treatment (Medications, Implantable Heart Device, Catheter Procedure, Open Heart Surgery, and Heart Transplant), End-Users (Hospitals and Clinics, Diagnostic Centers, Others), and Forecast Period 2021-2027

The global congenital heart disease market is anticipated to grow at a significant CAGR of nearly 9.1% during the forecast period. Congenital heart disease also called congenital heart defect is a condition having abnormalities in heart structure from birth time. The disease affects the heart walls, valves, and blood vessels of the heart. Its symptoms include shortness of breath, arrhythmias, cyanosis, edema, tiring quickly upon exertion. The rise in the incidences of congenital heart disease has been witnessed over the years. For instance, as per the Centers for Disease Control and Prevention (CDC), congenital heart defects (CHDs) affect nearly 1% of?or about 40,000?births per year in the US. Approximately 1 in 100 babies are born with a heart defect in the US annually.

Moreover, 25% of babies with CHD have a critical CHD. Infants with critical CHDs generally need surgery or other invasive procedures within their first year of life. Several industry participants in developed countries are expected to introduce devices for the treatment of defects, as well as an increase in healthcare spending across emerging countries, is to create opportunities in the market during the forecast period. However, a lack of awareness regarding the condition is hindering the growth of the market.

Impact Of COVID-19 Pandemic on the Global Congenital Heart Disease Market

The global congenital heart disease market was hit by the outbreak of COVID-19. The drug and device shortage during the COVID pandemic has led to an increasing focus of pharma companies' towards the delivery of drugs and devices quickly. The COVID-19 pandemic has disrupted the supply of medical devices and drugs across the globe. For instance, according to the National Institute of Health of the US, medication shortages in 2020 have been shown at 87% as compared to 2019. When contemplating the impact of the second wave of COVID-19 cases, the drug shortages may worsen. The market has impacted very little due to the continued demand for drugs and healthcare facilities during the pandemic.

Segmental Outlook

The global congenital heart market is segmented based on defect type, diagnosis, treatment, and end-user. Based on the defect type, the market is segmented into heart valve defects, heart wall defects, and blood vessel defects. Based on the diagnosis, the market is segmented into echocardiogram, chest X-ray, MRI scan, and others. Based on the treatment, the market is segmented into medications, implantable heart device, catheter procedures, open heart surgery, and heart transplant. Apart from this, by end-users, the market is segmented into hospitals and clinics, diagnostic centers, and others.

Global Congenital Heart Market Share by Treatment, 2020 (%)

Global Congenital Heart Market Share by Treatment

Catheter Segment holds the Significant Share in the Market

Among the treatment for congenital heart disease, the catheter segment held a potential share in 2020 and is also anticipated to grow during the forecast period. The catheter procedure allows doctors to repair congenital heart defects without surgically the chest and heart. Moreover, cardiac catheterization is used for the treatment of certain congenital heart diseases. It is used in conjunction with other tests such as an echocardiogram and MRI scans to diagnose heart defects. Thus, the growing demand for catheterization for the treatment of congenital heart disease is driving the market.

Regional Outlook

The market is further segmented based on regions including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, and Others0, and the Rest of the World (the Middle East and Africa, and Latin America). North America has been predicted to dominate the global congenital heart disease market due to well-established health infrastructure, technological developments, favorable government initiatives, and the significant prevalence of CHD.

Global Congenital Heart Disease Market Growth, by Region 2021-2027

Global Congenital Heart Disease Market Growth, by Region

Asia-Pacific is projected to have a considerable share in the global Congenital Heart Disease Market

Asia-Pacific is anticipated to hold a considerable market share during the forecast period. In the region, China and India are showing rapid progress. The increasing incidence and prevalence rate of congenital heart disease are the factors that are growing the market demand in the region. Additionally, the rising number of diabetic patients in the region is further propelling the market growth as congenital heart disease is common in people with diabetes. Moreover, the diabetes history in a family increases the risk of having congenital heart disease in newborns. China and India account for the highest cases of diabetes all across the globe. As per the IDF, China had the highest prevalence of diabetes (in the age range 20-79 years) in 2019 with around 116.5 million cases followed by India with around 77 million cases. By 2030, China and India are expected to maintain their first and second position globally in terms of the highest prevalence of diabetes with 140.5 million and 101.0 million cases, respectively. This, in turn, will likely result in the growing incidences of congenital heart defects in the region.

Market Players Outlook

Key players in the market include Abbott Laboratories, Boston Scientific Corp., Siemens Healthineers, Pfizer Inc., AstraZeneca Plc, Becton Dickson & Co., F. Hoffmann-La Roche Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in April 2021, Pfizer acquired Amplyx Pharmaceuticals, Inc. which is a privately-held company with its focus on the development of therapies for debilitating and life-threatening diseases.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global congenital heart disease market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Congenital Heart DiseaseIndustry
  • Recovery Scenario of Global Congenital Heart DiseaseIndustry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. BY Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of COVID-19 on Key Players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Congenital Heart Disease Market, By Defect Type
    • 5.1.1. Heart Valve Defects
    • 5.1.2. Heart Wall Defects
    • 5.1.3. Blood Vessel Defects
  • 5.2. Global Congenital Heart Disease Market, By Diagnosis
    • 5.2.1. Echocardiogram
    • 5.2.2. Chest X-Ray
    • 5.2.3. MRI Scan
    • 5.2.4. Others
  • 5.3. Global Congenital Heart Disease Market, By Treatment
    • 5.3.1. Medications
    • 5.3.2. Implantable Heart Devices
    • 5.3.3. Catheter Procedures
    • 5.3.4. Open Heart Surgery
    • 5.3.5. Heart Transplant
  • 5.4. Global Congenital Heart Disease Market, By End-User
    • 5.4.1. Hospitals and Clinics
    • 5.4.2. Diagnostic Centres
    • 5.4.3. Others

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbott Laboratories
  • 7.2. AstraZeneca Plc
  • 7.3. Becton Dickson & Co.
  • 7.4. Bio-Rad Laboratories
  • 7.5. Boston Scientific Corp.
  • 7.6. Laboratory Corporation of America Holdings (LabCorp)
  • 7.7. F. Hoffmann-La Roche Ltd.
  • 7.8. Glaxosmithkline Plc
  • 7.9. Janssen Pharmaceuticals, Inc.
  • 7.10. Medtronic
  • 7.11. Viatris Inc.
  • 7.12. Novartis Ag
  • 7.13. Pfizer, Inc.
  • 7.14. Randox Laboratories Ltd.
  • 7.15. Response Biomedical Corporation
  • 7.16. Sanofi S.A.
  • 7.17. Siemens Healthineers
  • 7.18. Thermo Fisher Scientific Inc.
  • 7.19. Vericel Corporation